Choose the surgeon-preferred
DuoVisc
®
OVD system, powered
by chondroitin sulfate.
1-4
TRIPLE-CHARGED FOR
SUPERIOR CORNEAL PROTECTION
1, 2,
†
Experience the superior endothelial protection
of VISCOAT
®
OVD and the excellent space
maintenance of ProVisc
®
OVD in one versatile
OVD system designed to meet your advanced
surgical needs.
1-3, 5-7, †
References
1. Glasser DB, Katz HR, Boyd JE, et al. Protective effects of viscous solutions in phacoemulsification and traumatic lens implantation. Arch Ophthalmol. 1989;107(7):1047-1051. 2. Petroll WM, Jafari M, Lane SS,
et al. Quantitative assessment of ophthalmic viscosurgical device retention using in vivo confocal microscopy.
J Cataract Refract Surg. 2005;31(12);2363-2368. 3.Lindstrom RL, Ong M. Protective effect of OVDs
against hydrogen peroxide-induced oxidative damage to corneal endothelial cells: in vitro model. Presented at ASCRS; 26 Mar 2011; San Diego, CA.
4. Alcon Data on File, 2020. 5. DuoVisc
®
Package �nsert.
6. Poyer JF, Chan KY, Arshinoff SA. New method to measure the retention of viscoelastic agents on a rabbit corneal endothelial cell line after irrigation and aspiration. J Cataract Refract Surg. 1998;24(1):84-90.
7. Labiris G, Sideroudi H, Rousopoulos K, et al. Cohesive versus dispersive-cohesive ophthalmic viscosurgical device in torsional intelligent phaco. J Cataract Refract Surg. 2015;41(3):681-682.
© 2021 Alcon, �nc. 10/21 US-DUV-2100006
For Important Product Information, please see adjacent page.
Activate the QR code
to learn why Alcon
OVDs have been
trusted in over 160
million procedures.
4
‡V�SCOAT
®
showed significantly lower superior corneal endothelial cell loss at 16 weeks post-op compared to HEALON*; n=59, P<0.01.
*Trademarks are the property of their respective owners.
